. 2026 May 8;16:1823078. doi: 10.3389/fonc.2026.1823078

Table 2.

Analysis of factors affecting PFS.

Factors	Analysis of single factors		Multiplicity
Factors	p-Value	HR (95% CI)	p-Value	HR (95% CI)
Group	0.021^*	0.465 (0.243–0.891)	0.005*	0.383 (0.196–0.750)
Control group vs observation group	0.021^*	0.465 (0.243–0.891)	0.005*	0.383 (0.196–0.750)
Gender	0.147	0.620 (0.325–1.184)
Male vs female	0.147	0.620 (0.325–1.184)
Age	0.797	1.091 (0.561–2.122)
<65 vs ≥65 years	0.797	1.091 (0.561–2.122)
Smoking history	0.476	1.294 (0.638–2.624)
No vs yes	0.476	1.294 (0.638–2.624)
ECOG PS	0.025^*	2.127 (1.101–4.110)	0.038*	2.016 (1.040–3.908)
<2 vs ≥2	0.025^*	2.127 (1.101–4.110)	0.038*	2.016 (1.040–3.908)
BMI (kg/m²)	0.506	0.803 (0.421–1.533)
18.5–23.9 vs <18.5 or ≥24.0	0.506	0.803 (0.421–1.533)
EGFR status at baseline	0.993	1.003 (0.527–1.906)
Exon 19del vs Exon21 L858R	0.993	1.003 (0.527–1.906)
Surgery/radiotherapy history	0.215	1.502 (0.789–2.861)
No vs yes	0.215	1.502 (0.789–2.861)
CNS metastasis	0.012^*	2.641 (1.241–5.619)	0.011*	2.688 (1.253–5.769)
No vs yes	0.012^*	2.641 (1.241–5.619)	0.011*	2.688 (1.253–5.769)
Tumor stage	0.979	1.028 (0.139–7.615)
IVa vs IVb	0.979	1.028 (0.139–7.615)

PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; BMI, body mass index; EGFR, epidermal growth factor receptor; CNS, central nervous system.

* indicates significant correlation at the 0.05 level (two-tailed).